ExpreS2ion Biotech Holding AB (EXPRS2) - Net Assets
Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has net assets worth Skr35.69 Million SEK (≈ $3.84 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr65.11 Million ≈ $7.01 Million USD) and total liabilities (Skr29.42 Million ≈ $3.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of ExpreS2ion Biotech Holding AB to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr35.69 Million |
| % of Total Assets | 54.81% |
| Annual Growth Rate | 27.51% |
| 5-Year Change | -74.57% |
| 10-Year Change | 177.07% |
| Growth Volatility | 109.89 |
ExpreS2ion Biotech Holding AB - Net Assets Trend (2013–2025)
This chart illustrates how ExpreS2ion Biotech Holding AB's net assets have evolved over time, based on quarterly financial data. Also explore ExpreS2ion Biotech Holding AB asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for ExpreS2ion Biotech Holding AB (2013–2025)
The table below shows the annual net assets of ExpreS2ion Biotech Holding AB from 2013 to 2025. For live valuation and market cap data, see EXPRS2 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr35.69 Million ≈ $3.84 Million |
-44.60% |
| 2024-12-31 | Skr64.42 Million ≈ $6.93 Million |
-1.44% |
| 2023-12-31 | Skr65.36 Million ≈ $7.03 Million |
-36.74% |
| 2022-12-31 | Skr103.33 Million ≈ $11.12 Million |
-26.38% |
| 2021-12-31 | Skr140.35 Million ≈ $15.10 Million |
+48.44% |
| 2020-12-31 | Skr94.55 Million ≈ $10.17 Million |
+8862.56% |
| 2019-12-31 | Skr-1.08 Million ≈ $-116.12K |
-113.00% |
| 2018-12-31 | Skr8.30 Million ≈ $893.32K |
+23.22% |
| 2017-12-31 | Skr6.74 Million ≈ $725.01K |
-47.69% |
| 2016-12-31 | Skr12.88 Million ≈ $1.39 Million |
+314.38% |
| 2015-12-31 | Skr-6.01 Million ≈ $-646.56K |
-355.94% |
| 2014-12-31 | Skr2.35 Million ≈ $252.63K |
+21.56% |
| 2013-12-31 | Skr1.93 Million ≈ $207.83K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ExpreS2ion Biotech Holding AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr15.69 Million | 43.97% |
| Other Comprehensive Income | Skr-187.08 Million | -524.24% |
| Other Components | Skr207.08 Million | 580.28% |
| Total Equity | Skr35.69 Million | 100.00% |
ExpreS2ion Biotech Holding AB Competitors by Market Cap
The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
XETRA:EFF
|
$794.86K |
|
Biodexa Pharmaceticals
NASDAQ:BDRX
|
$796.76K |
|
Cyber Security 1 AB
ST:CYB1
|
$797.10K |
|
Michelmersh Brick Holdings Plc
LSE:MBH
|
$799.73K |
|
CAT STRATEGIC MET.
F:8CHA
|
$793.95K |
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
$793.77K |
|
WICKET GAMING AB
F:7Q4
|
$792.19K |
|
NewGenIvf Group Limited Class A Ordinary Shares
NASDAQ:NIVF
|
$789.85K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ExpreS2ion Biotech Holding AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 64,799,000 to 35,686,000, a change of -29,113,000 (-44.9%).
- Net loss of 38,085,000 reduced equity.
- Share repurchases of 12,096,000 reduced equity.
- New share issuances of 12,096,000 increased equity.
- Other comprehensive income increased equity by 29,553,000.
- Other factors decreased equity by 20,581,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-38.09 Million | -106.72% |
| Share Repurchases | Skr12.10 Million | -33.9% |
| Share Issuances | Skr12.10 Million | +33.9% |
| Other Comprehensive Income | Skr29.55 Million | +82.81% |
| Other Changes | Skr-20.58 Million | -57.67% |
| Total Change | Skr- | -44.93% |
Book Value vs Market Value Analysis
This analysis compares ExpreS2ion Biotech Holding AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr10.65 | Skr2.09 | x |
| 2014-12-31 | Skr12.95 | Skr2.09 | x |
| 2015-12-31 | Skr-33.13 | Skr2.09 | x |
| 2016-12-31 | Skr45.36 | Skr2.09 | x |
| 2017-12-31 | Skr0.55 | Skr2.09 | x |
| 2018-12-31 | Skr0.56 | Skr2.09 | x |
| 2019-12-31 | Skr-0.07 | Skr2.09 | x |
| 2020-12-31 | Skr4.94 | Skr2.09 | x |
| 2021-12-31 | Skr4.35 | Skr2.09 | x |
| 2022-12-31 | Skr109.52 | Skr2.09 | x |
| 2023-12-31 | Skr56.66 | Skr2.09 | x |
| 2024-12-31 | Skr24.96 | Skr2.09 | x |
| 2025-12-31 | Skr12.54 | Skr2.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ExpreS2ion Biotech Holding AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1041.43%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.82x
- Recent ROE (-106.72%) is below the historical average (-65.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 35.66% | 10.33% | 1.62x | 2.13x | Skr495.54K |
| 2014 | 11.90% | 4.22% | 1.21x | 2.34x | Skr44.56K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-7.84 Million |
| 2016 | -66.29% | -183.53% | 0.19x | 1.91x | Skr-9.83 Million |
| 2017 | -145.98% | -100.41% | 0.57x | 2.56x | Skr-10.51 Million |
| 2018 | -202.65% | -189.69% | 0.42x | 2.52x | Skr-17.65 Million |
| 2019 | 0.00% | -120.78% | 0.74x | 0.00x | Skr-16.60 Million |
| 2020 | -33.54% | -603.02% | 0.04x | 1.26x | Skr-41.17 Million |
| 2021 | -31.30% | -359.04% | 0.08x | 1.08x | Skr-57.96 Million |
| 2022 | -114.79% | -2331.99% | 0.04x | 1.33x | Skr-128.94 Million |
| 2023 | -139.83% | -1296.47% | 0.09x | 1.20x | Skr-97.94 Million |
| 2024 | -55.62% | -1196.08% | 0.03x | 1.61x | Skr-42.52 Million |
| 2025 | -106.72% | -1041.43% | 0.06x | 1.82x | Skr-41.65 Million |
Industry Comparison
This section compares ExpreS2ion Biotech Holding AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ExpreS2ion Biotech Holding AB (EXPRS2) | Skr35.69 Million | 35.66% | 0.82x | $794.01K |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more